Annals of Oncology Advance Access originally published online on September 19, 2006
Annals of Oncology 2006 17(12):1749-1760; doi:10.1093/annonc/mdl302
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2006 European Society for Medical Oncology
hematologic malignancies |
Second malignancy risk associated with treatment of Hodgkin's lymphoma: meta-analysis of the randomised trials
1 German Hodgkin Study Group, University of Cologne, Germany
2 Rigshospitalet, Copenhagen, Denmark
3 University of La Sapienza, Rome, Italy
4 Oncology Hospital, National Medical Center, Mexico City, Mexico
5 University of Florence, Florence, Italy
6 Medical Radiological Research Centre, Obninsk, Russia
7 Istituto Nationale Tumore, Milan, Italy
8 Institut Bergonie, Bordeaux
9 Hopital Saint-Louis, Paris
10 Centre Regional Francoise Baclesse, Caen, France
11 Stanford University School of Medicine, Stanford, CA
12 St Judes Children's Research Hospital, Memphis, TN, USA
13 Hamilton Regional Cancer Center, Ontario, Canada
14 Duke University School of Medicine, Durham, NC, USA
15 FUNDALEU, Buenos Aires, Argentina
16 Christie Hospital, Manchester, UK
17 University Medical Center Nijmegen, Nijmegen, The Netherlands
18 Memorial Sloan-Kettering Cancer Center, New York, NY, USA
* Correspondence to: Dr J. Franklin, German Hodgkin Study Group, Herder Strasse 52-54, 50931 Koeln, Germany. Tel: +49-21-478-5894; Fax: +49-221-478-6311; E-mail: jeremy.franklin{at}uk-koeln.de
Background: Despite several investigations, second malignancy risks (SMR) following radiotherapy alone (RT), chemotherapy alone (CT) and combined chemoradiotherapy (CRT) for Hodgkin's lymphoma (HL) remain controversial.
Patients and Methods: We sought individual patient data from randomised trials comparing RT versus CRT, CT versus CRT, RT versus CT or involved-field (IF) versus extended-field (EF) RT for untreated HL. Overall SMR (including effects of salvage treatment) were compared using Peto's method.
Results: Data for between 53% and 69% of patients were obtained for the four comparisons. (i) RT versus CRT (15 trials, 3343 patients): SMR were lower with CRT than with RT as initial treatment (odds ratio (OR) = 0.78, 95% confidence interval (CI) = 0.62–0.98 and P = 0.03). (ii) CT versus CRT (16 trials, 2861 patients): SMR were marginally higher with CRT than with CT as initial treatment (OR = 1.38, CI 1.00–1.89 and P = 0.05). (iii) IF-RT versus EF-RT (19 trials, 3221 patients): no significant difference in SMR (P = 0.28) although more breast cancers occurred with EF-RT (P = 0.04 and OR = 3.25).
Conclusions: Administration of CT in addition to RT as initial therapy for HL decreases overall SMR by reducing relapse and need for salvage therapy. Administration of RT additional to CT marginally increases overall SMR in advanced stages. Breast cancer risk (but not SMR in general) was substantially higher after EF-RT.
Caution is needed in applying these findings to current therapies.
Key words: chemotherapy, Hodgkin's lymphoma, meta-analysis, radiotherapy, second malignancies
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  L. Lee, M. Pintilie, D. C. Hodgson, P. E. Goss, and M. Crump Screening mammography for young women treated with supradiaphragmatic radiation for Hodgkin's lymphoma Ann. Onc., January 1, 2008; 19(1): 62 - 67. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. K. Ng Second Cancers after Hodgkin's Lymphoma: Long-term Risks ASCO Educational Book, January 1, 2008; 2008(1): 418 - 422. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Engert, J. Franklin, H. T. Eich, C. Brillant, S. Sehlen, C. Cartoni, R. Herrmann, M. Pfreundschuh, M. Sieber, H. Tesch, et al. Two Cycles of Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine Plus Extended-Field Radiotherapy Is Superior to Radiotherapy Alone in Early Favorable Hodgkin's Lymphoma: Final Results of the GHSG HD7 Trial J. Clin. Oncol., August 10, 2007; 25(23): 3495 - 3502. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Ng and P. Mauch The impact of treatment on the risk of second malignancy after Hodgkin's disease Ann. Onc., December 1, 2006; 17(12): 1727 - 1729. [Full Text] [PDF]
|
|